Introduction {#s1}
============

Hereditary spastic paraplegias (HSPs) are a genetically heterogeneous group of neurodegenerative disorders with a prevalence of \~3-9/100,000 in most populations and a clinical hallmark of progressive lower limb weakness and spasticity ([@B1], [@B2]). HSPs result from genetic alterations resulting in dysfunction of the long axons in the corticospinal tract and posterior columns ([@B3]). Consistent with the cardinal clinical features of HSP, the primary pathological mechanism is distal axonal degeneration in a "dying-back" manner ([@B4]). HSPs are broadly categorized into pure and complicated forms based on the presence of additional clinical features such as ataxia, parkinsonism, peripheral neuropathy, cognitive dysfunction, cataracts, and icthyosis ([@B3]). HSPs segregate in several modes of inheritance, including autosomal dominant, autosomal recessive, X-linked, or mitochondrial ([@B3]). Although there is no evidence that HSP overall is more prevalent in one ethnic group over another, HSP does show ethnic differences in many of the mutated genes (Table [1](#T1){ref-type="table"}).

###### 

Critical review of the current SPG loci curated from the Online Mendelian Inheritance in Man (OMIM) database and a PubMed literature review of "hereditary spastic paraplegia" and each HSP gene and/or loci number.

  **Designation**   **Locus**       **Gene**   **Predominant phenotype**   **Inheritance**   **OMIM number**   **Year first reported**   **Publication count**   **Family count**   **Ethnicity**                                                                            **PubMed ID**
  ----------------- --------------- ---------- --------------------------- ----------------- ----------------- ------------------------- ----------------------- ------------------ ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  SPG1              Xq28            L1CAM      Complicated                 X-linked          303350            1986                      25+                     --                 --                                                                                       --
  SPG2              Xq22.2          PLP1       Complicated                 X-linked          312920            1987                      20+                     --                 --                                                                                       --
  SPG3A             14q22.1         ATL1       Pure                        AD                182600            1987                      100+                    --                 --                                                                                       --
  SPG4              2p22.3          SPAST      Pure                        AD                182601            1994                      200+                    --                 --                                                                                       --
  SPG5A             8q12.3          CYP7B1     Pure                        AR                270800            1994                      20+                     --                 --                                                                                       --
  SPG6              15q11.2         NIPA1      Pure                        AD                600363            1995                      12                      14                 Irish; Iraqi; Chinese; Japanese; Brazilian; Hungary                                      7825577; 14508710; 25341883; 21599812; 21419568; 17928003; 16795073; 16267846; 15643603; 27084228; 25133278; 24075313
  SPG7              16q24           SPG7       Pure or complicated         AR and AD         607259            1998                      60+                     --                 --                                                                                       --
  SPG8              8q24.13         WASHC5     Pure                        AD                603563            1999                      8                       19                 Caucasian; Brazilian; British; European; Dutch; Chinese; Japanese                        9973294; 10797436; 17160902; 23455931; 29768361; 27957547; 26967522; 25454649
  SPG9              10q23.3-q24.1   ALDH18A1   Complicated                 AD                601162            1999                      4                       9                  Italian; French; Spanish; Portuguese; Australian; Japanese                               9973297; 26026163; 26297558; 29915212
  SPG10             12q13.3         KIF5A      Pure                        AD                604187            1999                      40+                     --                 --                                                                                       --
  SPG11             15q21.1         SPG11      Complicated                 AR                604360            1999                      100+                    --                 --                                                                                       --
  SPG12             19q13.32        RTN2       Pure                        AD                604805            2000                      3                       4                  Welsh                                                                                    10677333; 22232211; 27165006
  SPG13             2q33.1          HSPD1      Pure                        AD                605280            2000                      3                       2                  French; Dutch                                                                            10677329; 11898127; 17420924
  SPG14             3q27-q28        SPG14      Complicated                 AR                605229            2000                      1                       1                  Italian                                                                                  10877981
  SPG15             14q24.1         ZFYVE26    Complicated                 AR                270700            2001                      11                      31                 Arab; Irish; Tunisian; French; Austrian; Italian                                         11342696; 17661097; 19438933; 18394578; 19805727; 27217339; 26492578; 24833714; 23733235; 19084844
  SPG16             Xq11.2          SPG16      Complicated                 X-linked          300266            1997                      2                       2                  Japanese; NA                                                                             9254866; 10982474
  SPG17             11q12.3         BSCL2      Complicated                 AD                270685            2001                      9                       23                 Austrian; English; Brazilian; Italian; Chinese; Portuguese; Korean; Dutch                11389484; 13680364; 14981520; 29934652; 25487175; 25219579; 18612770; 17486577; 16427281
  SPG18             8p1123          ERLIN2     Complicated                 AR and AD         611225            2011                      6                       7                  Turkish; Arabian; Northern European; Chinese; Saudi Arabian                              21330303; 23109145; 29528531; 27824013; 23085305; 21796390
  SPG19             9q              --         Pure                        AD                607152            2002                      1                       1                  --                                                                                       12112072
  SPG20             13q13.3         SPART      Complicated                 AR                275900            2002                      7                       8                  Amish; Omani; Turkish; Filipino; Moroccan                                                12134148; 18413476; 20437587; 26003402; 27112432; 28679690; 27539578
  SPG21             15q22.31        ACP33      Complicated                 AR                248900            2003                      2                       2                  Amish; Japanese                                                                          14564668; 24451228
  SPG23             1q24-q32        DSTYK      Complicated                 AR                270750            1985                      3                       3                  Middle Eastern                                                                           4061404; 14681889; 28157540
  SPG24             13q14           --         Pure                        AR                607584            2002                      1                       1                  Saudi Arabian                                                                            12499481
  SPG25             6q23-q24.1      --         Complicated                 AR                608220            2002                      1                       1                  Italian                                                                                  12070243
  SPG26             12p11.1-q14     B4GALNT1   Complicated                 AR                609195            2013                      2                       7                  Spanish; Portuguese; Tunisian; Bedouin                                                   23746551; 24283893
  SPG27             10q22.1-q24.1   --         Complicated                 AR                609041            2004                      1                       1                  French Canadian                                                                          15455396
  SPG28             14q22.1         DDHD1      Pure                        AR                609340            2005                      3                       4                  Moroccan; Turkish; French; Japanese                                                      23176821; 15786464; 27216551
  SPG29             1p31.1-p21.1    --         Complicated                 AD                609727            2005                      1                       1                  Scottish                                                                                 16130112
  SPG30             2q37.3          KIF1A      Pure                        AR and AD         610357            2011                      11                      17                 Palestinian; Algerian; Saudi Arabian; Brazilian; Macedonian; Korean; Sicilian; Chinese   21487076; 22258533; 25585697; 26410750; 27034427; 28332297; 28362824; 28834584; 28970574; 29159194; 29934652
  SPG31             2p11            REEP1      Pure                        AD                609139            2006                      30+                     --                 --                                                                                       --
  SPG32             14q12-q21       --         Complicated                 AR                611252            2007                      1                       1                  Portuguese                                                                               17515546
  SPG33             10q24.2         ZFYVE27    Pure                        AD                610244            2006                      1                       1                  German                                                                                   16826525
  SPG34             Xq24-q25        --         Pure                        X-linked          300750            2008                      1                       1                  Brazilian                                                                                18463901
  SPG35             16q23.1         FA2H       Complicated                 AR                612319            2008                      14                      28                 Arab; Omani; Pakistani; Filipino; Chinese; Italian; Turkish                              19068277; 20104589; 20853438; 22965561; 23566484; 23745665; 24359114; 24833714; 26344562; 27217339; 27316240; 28017243; 29376581; 29423566
  SPG36             12q23-q24       --         Complicated                 AD                613096            2009                      1                       1                  German                                                                                   19357379
  SPG37             8p21.1-q13.3    SPG37      Pure                        AD                611945            2008                      1                       1                  French                                                                                   17605047
  SPG38             4p16-p15        SPG38      Complicated                 AD                612335            2008                      1                       1                  Italian                                                                                  18401025
  SPG39             19p13.2         PNPLA6     Complicated                 AR                612020            2008                      5                       10                 Ashkenazi Jewish; German; Japanese; Brazilian                                            18313024; 24355708; 23733235; 25631098; 29248984
  SPG41             11p14.1-p11.2   SPG41      Pure                        AD                613364            2008                      1                       1                  Chinese                                                                                  18364116
  SPG42             3q25.31         SLC33A1    Pure                        AD                612539            2008                      1                       1                  Chinese                                                                                  19061983
  SPG43             19q12           C19ORF12   Complicated                 AR                615043            2013                      1                       1                  Malian                                                                                   23857908
  SPG44             1q42.13         GJC2       Complicated                 AR                613206            2009                      1                       1                  Italian                                                                                  19056803
  SPG45             10q24.3-q25.1   NT5C2      Complicated                 AR                613162            2009                      3                       2                  Turkish; Qatari                                                                          19415352; 24482476; 28327087
  SPG46             9p13.3          GBA2       Complicated                 AR                614409            2013                      6                       12                 Tunisian; Cypriot; Chinese                                                               23332916; 23332917; 24252062; 29524657; 27553021; 24337409
  SPG47             1p13.2          AP4B1      Complicated                 AR                614066            2011                      7                       13                 Israeli; Arab; Turkish; African American                                                 24781758; 22290197; 24700674; 24781758; 29193663; 27625858; 25693842
  SPG48             7p22.1          AP5Z1      Pure                        AR                613647            2010                      3                       4                  French; Moroccan                                                                         20613862; 24833714; 26085577
  SPG49             14q32.31        TECPR2     Complicated                 AR                615031            2012                      3                       3                  Jewish Bukharian                                                                         23176824; 25590979; 27406698
  SPG50             7q22.1          AP4M1      Complicated                 AR                612936            2009                      4                       5                  Moroccan; Turkish; Greek                                                                 19559397; 21937992; 24700674; 29096665
  SPG51             15q21.2         AP4E1      Complicated                 AR                613744            2011                      4                       4                  Palestinian; Syrian; Moroccan                                                            20972249; 21620353; 21937992; 23472171
  SPG52             14q12           AP4S1      Complicated                 AR                614067            2011                      3                       5                  Syrian; Caucasian; Albanian; Italian                                                     21620353; 25552650; 27444738
  SPG53             8p22            VPS37A     Complicated                 AR                614898            2012                      1                       2                  Arab                                                                                     22717650
  SPG54             8p11.23         DDHD2      Complicated                 AR                615033            2012                      4                       9                  Dutch; Canadian; Omani; Iranian                                                          23176823; 23486545; 24482476; 27679996
  SPG55             12q24.31        C12ORF65   Complicated                 AR                615035            2012                      3                       3                  Japanese; Indian                                                                         24080142; 24198383; 23188110
  SPG56             4q25            CYP2U1     Complicated                 AR                615030            2012                      6                       9                  Saudi Arabian; Southern Italian; Iranian; Japanese; Turkish; Italian                     23176821; 24337409; 26936192; 27292318; 28725025; 29034544
  SPG57             3q12.2          TFG        Complicated                 AR                615658            2013                      5                       6                  Indian; Italian; Pakistan; Sudanese; British Pakistani; northern Indian                  23479643; 29971521; 28124177; 27601211; 27492651
  SPG58             17p13.2         KIF1C      Complicated                 AR and AD         --                2014                      3                       6                  Palestinian; Moroccan; Turkish                                                           24319291; 24482476; 29544888
  SPG61             16p12.3         ARL6IP1    Complicated                 AR                615685            2014                      1                       1                  --                                                                                       24482476
  SPG62             10q24.3         ERLIN1     Complicated                 AR                615681            2014                      1                       3                  --                                                                                       24482476
  SPG63             1p13.3          AMPD2      Complicated                 AR                615686            2014                      1                       1                  --                                                                                       24482476
  SPG64             10q24.1         ENTPD1     Complicated                 AR                615683            2014                      1                       2                  --                                                                                       24482476
  SPG72             5q31.2          REEP2      Pure                        AR/AD             615625            2014                      2                       3                  French; Portuguese; --                                                                   24388663;28491902
  SPG73             19q13.33        CPT1C      Pure                        AD                616282            2015                      1                       1                  --                                                                                       25751282
  SPG74             1q42.1          IBA57      Complicated                 AR                616451            2015                      1                       1                  Arab                                                                                     25609768
  SPG75             19q13.1         MAG        Complicated                 AR                616680            2014                      2                       2                  Pakistani; --                                                                            26179919; 24482476
  SPG76             11q13.1         CAPN1      Complicated                 AR                616907            2016                      4                       9                  Moroccan; Utah; Irish; Italian                                                           27153400; 29678961; 27320912; 28566166
  SPG77             6p25.1          FARS2      Pure                        AR                617046            2015                      3                       4                  Chinese; European                                                                        25851414; 26553276; 29126765
  SPG78             1p36.1          ATP13A2    Complicated                 AR                617225            2016                      2                       4                  Pakistani; Bulgarian                                                                     27217339; 28137957
  SPG79             4p13            UCHL1      Complicated                 AR                615491            2013                      3                       3                  Turkish; Norwegian; Indian                                                               23359680; 28007905; 29735986

As with many other Mendelian diseases, the introduction of next-generation sequencing (NGS) revolutionized the genetic diagnosis of HSPs with over 76 genomic loci and 58 corresponding genes ([@B5]). The autosomal dominant (AD) HSPs lead mostly to the pure form of disease and are linked to 19 spastic gait (SPG) genes. The most common AD genes are SPG4/*SPAST*, SPG3A/*ATL1*, SPG31/*REEP1*, and SPG10/*KIF5A*. Complicated HSPs more frequently occur in autosomal recessive (AR) families and are linked to 57 loci and 52 genes. The most common AR genes are SPG11/*KIAA1840*, SPG5A/*CYP7B1*, SPG7, and SPG15/*ZFYVE26*. Though rare, X-linked and mitochondrial inheritance are also observed. In the past 5 years alone \>15 novel HSP and HSP-related genes have been reported. However, the number of families identified in the initial and follow-on papers is typically low; for example, the original *REEP2* publication had 2 families with a follow-on of a single family ([@B6], [@B7]). Furthermore, a large number of recent SPG loci are supported by a single publication only (Table [1](#T1){ref-type="table"}). This has led to the concern that we are in an asymptotic situation where, even with many new genes, the diagnostic yield may not get close to 100%. This potential gap in heritability is observed in other rare disorders as well and might be referred to as "dark matter" of clinical genomics. This review will focus on potential causes and efforts to overcome these challenges.

The "dark matter" of clinical genomics {#s2}
======================================

It is usually assumed that HSP is caused by Mendelian mechanisms and that eventually nearly all patients will receive a single-gene diagnosis. However, this is not necessarily true. Related disorders illustrate a diverse situation: inherited neuropathies (Charcot-Marie-Tooth disease, CMT) are also highly heterogeneous Mendelian disorders whereas amyotrophic lateral sclerosis (ALS) is largely not explained by Mendelian genes. The proportion of Mendelian genes is even lower in late onset neurodegenerative diseases, such as Parkinson and Alzheimer disease.

The reported diagnostic yield for exome sequencing in the general clinical setting ranges from 25 to 50% ([@B8], [@B9]). In hereditary spastic paraplegias, Schüle et al. identified a molecular diagnosis in 46% of families (240/519 families), despite extensive whole-exome sequencing efforts, with low success in simplex families (28%) ([@B2]). Similarly, a 20% diagnostic yield was reported in a cohort of 98 previously unsolved HSP families analyzed by a custom sequencing panel of 70 HSP and HSP-related genes ([@B10]).

While the genetics of certain neurodegenerative diseases are deemed "complex," the field, thus far, has not applied similar models of inheritance to HSP. We believe that it is too early to tell whether non-Mendelian effects have a major contribution to HSP. There are a number of valid pro-Mendelian hypotheses as to how to close the diagnostic gap, and the coming years will allow us to test these ideas (Figure [1](#F1){ref-type="fig"}). These include non-coding regions of the genome, unorthodox types of mutations (such as repeat expansions) and digenic inheritance models. However, the search for risk genes and alleles will likely contribute to the understanding of HSP in multiple ways, from exploring oligogenic causation, gene/environment interactions, and phenotype modifying genes; thus, expanding the inheritance models in HSP.

![The diagnostic heritability gap in HSP. **(A)** Despite unprecedented success in the identification of additional Mendelian genes, the diagnostic yield may not get close to 100% in HSP, but rather reach an asymptotic ceiling. **(B)** Areas that are potentially understudied in HSP thus far for cost and technical challenges. These include uncommon Mendelian causation, but also modifier and oligogenic risk alleles. The colored bars represent genes, the black lines connecting genes represent noncoding regions, and each "X" represents a mutation.](fneur-09-00958-g0001){#F1}

The continued search for mendelian causes {#s3}
=========================================

Systematic reanalysis of unresolved clinical exomes can reveal causative variants that were not prioritized in the initial analysis and increase the diagnostic yield; however, the search should ideally be expanded beyond mutations in the protein-coding regions ([@B11]). Full exploration of the non-coding space will require whole-genome sequencing; however, fortunately, the untranslated regions and regions adjacent to exons are typically covered by whole-exome sequencing. Though sparse annotation poses considerable challenges in interpreting these variants, Minnerop et al. found deep intronic mutations in *POLR3A* to be a frequent cause of HSP and cerebellar ataxia. After identifying intronic variants in a single recessive spastic ataxia family, the authors screened a cohort of 618 cases. They found that compound heterozygous *POLR3A* mutations accounted for \~3.1% of genetically unclassified autosomal recessive and sporadic index cases. Over 80% of these cases shared the same deep-intronic mutation which activates a cryptic splice site. This study nicely demonstrates the potential held within the non-coding genome.

As the limitation of non-coding coverage is overcome by whole-genome sequencing, the clinical and functional interpretation of variants will remain a challenge. Recently, the complementation of genetic sequencing with transcriptome sequencing (RNA-seq) has successfully improved the diagnostic yield in Mendelian disorders ([@B12], [@B13]). RNA-seq adds a functional layer to help prioritize genes and variants by providing information about aberrant splicing, abnormal gene expression levels, and extreme cases of mono-allelic expression ([@B13]). Since gene expression and mRNA isoforms vary widely across tissues, sequencing disease-relevant tissue is critical to the potential value with this approach ([@B12]). Due to the difficulties in obtaining the disease-relevant tissue, transcriptome sequencing may have limited potential in HSP. However, the recent mapping of the axonal transcriptome from induced pluripotent stem cell derived motor neurons may provide an avenue to overcoming this challenge ([@B14]).

Another contributor of genome variability that could help resolve the diagnostic gap is structural variation, including copy number variations, translocations, and inversions ([@B15]). Copy number variations (CNVs), in particular, are known to play an important role in HSPs, causing 8%-41% of SPG4 due to the *Alu* genomic architecture of *SPAST* ([@B16]--[@B19]). Screening of approximately 600 independent HSP cases over a 5-year period in *ATL1, SPAST, NIPA1, SPG7*, and *REEP1* has detected numerous deletions ([@B20]). Recently, a complex homozygous 4-kb deletion/20-bp insertion that removes the last two exons and part of the 3′UTR was identified in *DSTYK* ([@B21]). These studies exemplify the relevance of structural variation in HSPs. However, major challenges still exist that hinder full exploration of these mutations. Since CNVs are also a large source of normal variation and their pathogenic potential can depend on genetic ancestry and environmental factors, determining whether a CNV is benign or pathogenic remains a considerable clinical challenge ([@B15], [@B22]). Additionally, CNV detection from whole-exome sequencing remains immature and unstable, as indicated by the low concordance between CNV variant callers ([@B23]). Another popular method for CNV detection is high-resolution microarray, which is commonly used in clinical cytogenetics where sequencing based analysis can overwhelm a typical laboratory\'s workflow ([@B24]). Though research laboratories largely rely on NGS, the additional high-resolution microarrays may lead to diagnoses in cases with suspected CNV. Improved sequencing technology and structural variation interpretation and detection will resolve more HSP families in the future.

Underappreciated rare genomic mechanisms {#s4}
========================================

Standard clinical genomic analysis focuses on typical modes of inheritance, such as autosomal dominant, autosomal recessive, and X-linked, while unusual inheritance modes are often ignored. Inclusion of these "genomic" mechanisms in analysis pipelines, for example genomic imprinting, repeat expansions, and uniparental disomy, can lead to successful identification of overlooked molecular diagnoses.

Uniparental isodisomy is particularly relevant to HSPs as this mechanism has been observed in two autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) cases, one SPG18 case, and four SPG35 cases ([@B25]--[@B27]). Uniparental isodisomy is the inheritance of both chromosomes from the same parent, resulting from errors in meiosis and/or mitosis ([@B28]). Isodisomic events generate regions of homozygosity in the offspring, allowing for the inheritance of a homozygous variant from one heterozygous carrier-parent ([@B29]). During trios analysis, these homozygous variants are usually discarded as sequencing errors since only one parent is a carrier. The occurrence of uniparental isodisomy can be inferred from very long regions of homozygosity that are isolated to a single chromosome; therefore, uniparental isodisomy detection can be incorporated into a standard whole-exome pipeline by modifying existing methods for long regions of homozygosity ([@B30], [@B31]). The high number of SPG35 cases resulting from UPD suggests that this may be a frequent genetic mechanism for *FA2H* homozygous mutations in non-consanguineous families ([@B27]). Uniparental isodisomy is important to detect because of its impact on molecular diagnosis and recurrence risk in families.

The awareness of the genetic overlap between HSPs and spinocerebellar ataxias (SCAs) has increased as the number of loci causing both diseases expands; however, the overlap of HSP and SCA caused by triplet-repeat expansions is less emphasized ([@B32]). Bettencourt et al. reviewed the literature of triplet-repeat expansions mimicking spastic paraplegias: expansions have been observed at the *ATXN1, ATXN2, ATXN3, ATXN7, ATN1*, and *FXN* loci ([@B32]). The authors recommend incorporating triplet-repeat ataxia analysis into diagnostic algorithms, especially *ATXN3* in autosomal dominant complicated HSP and *FXN* in autosomal recessive or sporadic spastic paraplegias ([@B32]). It is conceivable that additional, yet to be identified, coding and non-coding repeat expansion loci cause HSP.

Beyond mendelian inheritance {#s5}
============================

Based on the assumption of fully penetrant alleles, traditional Mendelian disease analysis focuses on the rare DNA variation that segregates within a family. However, these locus-specific family studies treat Mendelian traits as distinct entities and disregard a more comprehensive genetic model for human disease in which variants of varying effect size as well as environmental influences contribute to disease ([@B33]). The challenge is the unexpected large amount of variation in the human genome on a population level, where \>99% of all variants show a minor allele frequency of \< 1% ([@B34]). Since many of these variants are without phenotypic consequence, some certainly are very harmful, and a considerable number must have effect sizes that are below the threshold of a Mendelian gene but contribute significantly to phenotypic expression. Identification of strong effect sizes in the background of mostly minor effects is the next big challenge in human genetics. Recent method developments in statistical genetics allow for unbiased genome-wide screens for non-Mendelian alleles, and surprisingly, are able to re-identify *bona fide* Mendelian genes as well ([@B35]). The application to HSP genomics will eventually generate a more complete genetic architecture of the disease.

Reduced penetrant and risk alleles
----------------------------------

Contrary to general expectations for HSP families, asymptomatic carriers are not infrequent, in which case, the genotype is said to be incompletely penetrant ([@B36], [@B37]). Reduced and age-dependent penetrance is a diagnostically challenging situation observed in autosomal dominant HSPs, especially SPG3A, which can lead to misinterpretation of inheritance patterns due to asymptomatic carriers and exclusion of the disease-causing allele ([@B38]--[@B40]). Additionally, sex-dependent penetrance is suspected in *SPAST* and *ATL1* based on the excess of affected males ([@B41]). Incomplete penetrance can also manifest in autosomal recessive disorders when the primary mutation leads to varying phenotypic effects depending on the secondary mutation ([@B36]). For example, novel compound heterozygous mutations in *SPG11* let to an atypical late onset and mild form of SPG11 ([@B42]).

To distinguish reduced-penetrance alleles, which have caused HSP in at least some individuals under a Mendelian trait, risk alleles have been defined as variants with smaller effect sizes that are part of a multifactorial model of disease causation ([@B36]). However, since the possibility of risk alleles is only recently recognized in rare Mendelian disease, the line between penetrance and risk is often blurred. In this context, risk alleles more broadly refer to rare variants that may lead to a less severe, later-onset form of disease or contribute to an individual\'s susceptibility to disease, likely through an oligogenic model. For example, heterozygous mutations in *SPG7* were identified as a potential susceptibility factor for late-onset neurodegenerative disorder ([@B43]). Similarly, heterozygous mutations in *MME* were recently shown to predispose carriers to late-onset axonal neuropathy ([@B44]). In MME, the comparison of the "rare variant load" of missense and loss of function changes in late-onset CMT to the general population showed a significant enrichment of such variation ([@B44]).

Systematic identification of rare variant associations are usually limited by low statistical power unless sample sizes or variant effect sizes are very large ([@B45]). To illustrate, \>60,000 cases (and an equal number of controls) would be necessary to detect a disease association for a rare variant (0.1% frequency) with an odds ratio of 2.0 for a disease with a 5% population prevalence ([@B45]). Fortunately, powerful study designs can alleviate the sample size requirement to more reasonable numbers ([@B46]). One approach that can be explored in HSPs is the gene-based variant burden test which collapses the number of minor alleles into one genetic score (gene), thus reducing multiple testing and increasing power ([@B45], [@B47]). One successful example of this approach was the identification of a new ALS gene, *TBK1*, in 2,869 sporadic ALS patients ([@B35]). Remarkably, other known ALS genes showed strong associations, indicating that additional variation in known familial ALS genes also contribute to sporadic ALS forms ([@B35]). The rare variant association studies are particularly useful for identifying risk genes and novel gene associations.

Modifier alleles
----------------

An increasing number of exceptions to the fundamental "one gene, one phenotype" paradigm are being published across Mendelian phenotypes ([@B48]). The oversimplified view that phenotypic expression, even for classically monogenic disorders, is driven exclusively by mutations at a single locus is being replaced by the concept of genetic modification ([@B49]). Though several types of genetic modification are possible, the simple definition is the effect of one allele on the phenotypic outcome of a second allele ([@B49]). If the primary allele is sufficient to cause disease, then the secondary allele is a "modifier" that modulates phenotypic expression, such as disease severity or progression.

Given the high clinical variability observed across HSP patients, genetic modification of the primary allele was anticipated. Over a decade ago, intragenic polymorphisms were suggested to modify the age at onset of *SPAST* mutations ([@B50], [@B51]). More recently, *SPAST* deletions spanning the adjacent *DPY30* gene were shown to have significantly reduced age at onset ([@B52]). Furthermore, in a study of a large Cuban spinocerebellar ataxia type 2 (SCA2) cohort, 33% of the residual age at onset variance was attributed to genetic modifiers ([@B53]). Examples of genetic modifiers from related Mendelian disorders exist in the literature; for instance, a polymorphism in miR-149 was recently associated with onset age and severity in Charcot-Marie-Tooth disease type 1A (CMT1A) ([@B54]).

Another study design that increases the statistical power for association testing of rare variants is the extreme phenotype sampling (EPS) approach ([@B46]). Based on the assumption that rare causal variants are more likely found in the extremes of a quantitative trait such as age of onset or severity of a symptom, EPS can increase the power to detect rare variants over random sampling ([@B46]). For example, Emond et al. utilized an extreme phenotype sampling approach to identify an association between rare coding variants in *DCTN4* and time to first *Pseudomonas* infection (measure of cystic fibrosis severity) ([@B47], [@B55]). Additionally, Tao et al. identified *SIPA1L2* as a genetic modifier of muscle strength impairment in CMT1A. *In vitro* knock down of *SIPA1L2* in Schwannoma cells lead to a significant reduction in *PMP22* expression, offering a potential pathway for therapeutic strategies ([@B56]). Application of EPS to an HSP cohort may also reveal modifier alleles that contribute to disease.

Oligogenic inheritance
----------------------

Digenic or oligogenic inheritance refers to instances when one primary allele is insufficient to cause disease, instead requiring the combined consequence of multiple alleles ([@B49]). Evidence of oligogenic inheritance has emerged in other neurological disorders. In both sporadic and familial amyotrophic lateral sclerosis (ALS) cases, patients harboring two or more rare variants had lower survival or earlier age at onset, suggesting that the combined effect of rare variants affects ALS development and progression ([@B57]--[@B59]). Similarly, over 30% of Parkinson\'s disease (PD) patients carried additional rare variants in Mendelian PD genes and had younger ages at onset ([@B60]). An increased rare variant burden was also observed in two cohorts of inherited neuropathy cases, which was followed up *in vivo* zebrafish experiments ([@B61]). In zebrafish, more severe phenotypic outcomes were observed as a consequence of increased mutational burden in neuropathy genes, consistent with a positive genetic interaction mechanism of oligogenic inheritance ([@B61]).

Demonstrating oligogenic inheritance from family studies is challenging without experimental models. However, one trending approach to assessing oligogenic inheritance---which has been explored in Parkinson, ALS, Frontotemporal Dementia, Congenital Hypothyroidism, Inherited Neuropathy, and more---is to evaluate the mutational burden across known disease genes through Fisher\'s exact test or logistic regression ([@B60]--[@B64]). However, caution should be used with this approach as Koegh et al. warns that systematic bias can lead to the apparent enrichment of "oligogenic" variants in familial cases and controlling such bias is essential for investigating an oligogenic role in neurodegenerative diseases ([@B65]).

Connecting the many loci: a network biology approach {#s6}
====================================================

Though the high amount of locus heterogeneity present in HSPs complicates clinical diagnosis, it does provide an opportunity to study the overarching biological pathways through analysis of molecular networks. Genes and their products form complex networks within cells that are governed by specific laws and principles ([@B66]). These complex networks model the non-linear genotype-phenotype relationships observed in HSPs, such as incomplete penetrance and epistasis, that deviate from the "one gene, one phenotype" principle ([@B66], [@B67]). Functionally related proteins interact with each other to accomplish similar biological mechanisms, thus forming cellular pathways ([@B66]). Network medicine capitalizes on these interactions and hypothesizes that perturbation of a single gene product will propagate along the entire network ([@B68]). The interactions between a set of disease-causing genes can be summarized into a disease module for further study ([@B69]). A disease module can be analyzed for differences in complete loss of gene products vs. interaction-specific perturbations, global relationships to other human diseases, novel candidate disease genes, and emerging biological pathways ([@B68], [@B70]--[@B73]). Novarino et al. combined exome sequencing with network analysis to summarize a global view of HSP ([@B74]). A HSPome was created from previously published HSP seed genes and candidate genes from whole exome sequencing. From the HSPome, they extracted subnetworks of functionally related proteins that form pathological modules, including ER-associated degradation, endosomal and membrane-trafficking, and purine nucleotide metabolism. Three candidate genes arose from the HSPome that were found to be mutated in HSP patients. Lastly, the authors discovered the HSP seed genes were significantly overlapping with amyotrophic lateral sclerosis, Alzheimer\'s disease, and Parkinson\'s disease, while no overlap was observed between HSP and neurodevelopmental disorders nor non-neurological disorders ([@B74]). Recently, the relationship between the inherited axonopathies, HSP and Charcot-Marie-Tooth 2 (CMT2), was explored through a network analysis of protein-protein interactions. The HSP disease module was found to significantly overlap both the CMT2 and hereditary ataxia modules. Pathway analysis revealed ribosomal protein and viral infection response pathways ([@B75]). With the rapid pace of gene discovery in HSPs, network analysis will continue to be a powerful approach for deciphering the complex interactions underlying the phenotype.

Overcoming the phenotypic divide {#s7}
================================

Historically, many movement disorders, including HSPs, have been clinicogenetically classified based on the predominant phenotype of the first gene locus ([@B76]). These classification systems have similar shortcomings, including erroneously assigned loci, duplicated loci, missing loci, and unconfirmed loci ([@B76], [@B77]). Furthermore, these classification systems suggest that HSPs are a distinct and isolated disorder, when in fact HSPs exist on a spectrum between inherited ataxias and axonal Charcot-Marie-Tooth disease (CMT2) ([@B76], [@B78]). Not only do these disorders share clinical symptoms, such as prominent lower extremity spasticity, but they can also be caused by mutations within the same genes ([@B76], [@B78], [@B79]). Next-generation sequencing greatly facilitated the appreciation of these genetic overlaps by providing an unbiased approach that broke through the prior clinical and diagnostic preconceptions ([@B76]). Phenotypic expansions continue to blur the lines drawn in neurological disorders; for example, HSP was recently associated to *PLA2G6*, the causative gene underlying heterogeneous PLA2G6-associated neurodegeneration (PLAN) ([@B80]). Additionally, *KIF5A*, known to cause both HSP and CMT2, contains a C-terminal hotspot of mutations that can cause a classical amyotrophic lateral sclerosis phenotype ([@B81]). Furthermore, mutations in *ATP13A2*, originally linked to a rare form of juvenile-onset atypical Parkinson disease (Kufor-Rakeb syndrome), are now also associated with neurodegeneration with brain iron accumulation, neuronal ceroid lipofuscinosis, and most recently, complicated HSP ([@B82]--[@B84]). Awareness and consideration of phenotypic expansions will be essential for both individual genetic diagnoses as well as revealing common pathways underlying neurodegeneration ([@B80]). As the phenotypic spectrum broadens across the neurologic community, these historical classifications are being reconsidered ([@B78]). To address this issue, Synofzik and Schüle have proposed a mechanism based classification system for the ataxia-spasticity spectrum, based on unbiased modular phenotyping, that captures nuanced phenotypic expression, opens ataxia and spasticity to a multisystem neuronal dysfunction, and help to prioritize research on shared pathways ([@B76]).

The necessity of data aggregation and collaboration {#s8}
===================================================

The above-mentioned approaches increasingly require larger datasets which contradicts, of course, the low prevalence of rare disease. This requirement exceeds what single labs have traditionally been able to collect from local clinics. It will be insufficient to exchange candidate gene information or candidate alleles. To apply statistical approaches, one needs to gather hundred if not thousands of HSP samples and adequate controls. This led to the notion of raw genetic data aggregation as the next frontier for HSP gene discovery. The most prominent example of systematic data aggregate in HSP is the GENESIS Project database (tgp-foundation.org). Over 600 HSP, 500 ataxia, and 890 CMT exomes or genomes have been aggregated from several dozen laboratories in 22 different countries([@B85]). We have begun to complement Mendelian gene discovery efforts with modifier gene studies and rare variant burden analyses. It is still early, but it appears that significant results can be achieved beginning with 200+ exomes and sufficient control samples. For example, an exome-wide association study with 202 cases and 6,905 controls successfully found a signal in *GREB1L* (joint *p*-value = 2.3 × 10^−7^) in renal agenesis and hypodysplasia ([@B86]). Another exome-wide association study in CMT, with 343 cases and 935 controls, identified a significant association in *EXOC4* (*p*-value = 6.9 × 10^−6^, OR = 2.1) and nominal associations with other known CMT genes ([@B87]).

Concluding remarks {#s9}
==================

The current period is a remarkable time for HSP research. Studies from many countries are reporting a steady pace of novel Mendelian genes, complementing existing multigene clinical panels. The diagnostic yield has never been higher; albeit it is hindered by an increasing burden of Variants of Uncertain Significance. In addition, gene therapy approaches are maturing in related disorders, and it appears only a matter of time before they are applied to specific HSP genes. These novel therapeutic approaches include gene replacement, antisense oligonucleotides (ASO), and soon gene editing. Most of them require a specific genetic diagnosis. This emphasizes the need to fill the diagnostic gap currently estimated at 30-40%, but larger for sporadic HSP cases.

Contemplating the details of recently discovered HSP genes suggests that traditional Mendelian mutations may not be able to account for the majority of yet to be diagnosed patients. We have outlined the various possibilities of non-protein coding Mendelian variation but also an increasing interest in multigene causation or phenotypic modification. It appears to soon to tell how the genetic architecture of HSP will look like in 10 years\' time. However, we are certain that non-Mendelian elements will play a role, if only as secondary protective/worsening factors. Still, cohort approaches now enabled through extensive collaborations and data aggregations will likely also hold surprises for non-traditional disease causation in HSP.
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